Maze Therapeutics (NASDAQ:MAZE) Downgraded to Sell Rating by Wall Street Zen
by Amy Steele · The Cerbat GemWall Street Zen lowered shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) from a hold rating to a sell rating in a research note released on Saturday morning.
Several other analysts have also recently weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim increased their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $66.00.
Check Out Our Latest Stock Analysis on MAZE
Maze Therapeutics Price Performance
Maze Therapeutics stock opened at $28.09 on Friday. The firm has a 50 day simple moving average of $40.60 and a 200-day simple moving average of $38.21. Maze Therapeutics has a 1-year low of $7.16 and a 1-year high of $53.65. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -8.70 and a beta of 5.16.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08.
Insider Buying and Selling
In related news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total transaction of $332,025.00. Following the completion of the transaction, the insider owned 10,503 shares of the company’s stock, valued at approximately $464,967.81. This trade represents a 41.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the sale, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 95,000 shares of company stock valued at $4,245,625.
Institutional Investors Weigh In On Maze Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after buying an additional 362,060 shares in the last quarter. Woodline Partners LP lifted its holdings in Maze Therapeutics by 10.0% during the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after buying an additional 94,529 shares in the last quarter. Marshall Wace LLP lifted its holdings in Maze Therapeutics by 9.0% during the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after buying an additional 69,771 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in Maze Therapeutics by 40.8% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 767,383 shares of the company’s stock worth $31,793,000 after buying an additional 222,251 shares in the last quarter.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.